Accelerating Progression of TTX-381 through the Value Chain to Address Blindness in CLN2 Batten Disease
Time: 10:00 am
day: Conference Day Two
Details:
- Discussing the need for rapid development of Tern Therapeutics TTX-381 to preserve vision in patients with CLN2 Disease
- Highlighting the steps taken to maximize speed of development, including novel preclinical, clinical, regulatory, and CMC approaches
- Evaluating implications for rapid development of gene therapies for other rare ophthalmic diseases
